8-K: Ekso Bionics Reports Record Q4 Revenue and Improved Gross Margins in Full-Year 2024 Results

Ekso Bionics announced record fourth-quarter revenue and improved gross margins in its full-year 2024 financial results, highlighting growth in exoskeleton technology for medical and industrial use.

Summary

• Ekso Bionics reported its financial results for the three and twelve months ended December 31, 2024.
• The company achieved record Q4 2024 revenue of $5.1 million, a 5% increase compared to $4.8 million in the same period of 2023.
• Q4 2024 gross margin increased by 400 basis points year-over-year to 53%.
• For the full year 2024, revenue was $17.9 million, a slight decrease of 2% compared to $18.3 million in 2023.
• Full-year gross margin improved to 53% from 50% in the previous year.
• The net loss applicable to common shareholders for the full year 2024 was $11.3 million, or $0.56 per share, a 25% improvement compared to a net loss of $15.2 million, or $1.10 per share, in 2023.
• As of December 31, 2024, the company had cash and restricted cash of $6.5 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to record Q4 revenue, improved gross margins, and a reduced net loss. However, the decrease in full-year revenue and ongoing net losses temper the overall outlook.

Positives

• Record Q4 2024 revenue indicates strong sales performance in the final quarter of the year.
• Improved gross margin in Q4 2024 and full year 2024 suggests better cost management and pricing strategies.
• The 25% reduction in net loss for the full year 2024 demonstrates progress towards profitability.
• Cost savings in supply chain and a reduction in service costs contributed to the increase in gross profit.
• Lower sales and marketing, research and development, and general and administrative expenses contributed to the reduced net loss.
• The appointment of National Seating & Mobility as an exclusive distributor could expand market reach.

Negatives

• Full-year revenue decreased by 2% compared to the previous year, indicating a slight decline in overall sales.
• The company still reported a net loss of $11.3 million for the full year, despite improvements.
• The company used $9.8 million of net cash in operations for the full year ended December 31, 2024.
• Cash and restricted cash decreased from $8.6 million to $6.5 million year over year.

Risks

• The company's inability to obtain adequate financing to fund and grow operations.
• Challenges in collaborating with neuro-rehabilitation facilities and physicians to secure CMS reimbursements.
• The risk of not obtaining future reimbursements from CMS in a timely manner or at expected levels.
• The company's ability to raise funds to operate and grow its business.
• The company's inability to obtain insurance coverage beyond CMS.
• The company's inability to obtain additional indications of use for its devices.
• The significant length of time and resources associated with product development.
• The failure to achieve broad market acceptance of the company's products.
• Adverse results in future clinical studies of the company's medical device products.
• Disruptions in the company's supply chain.

Future Outlook

The company's focus will be on aggressively executing two key pillars of its growth strategy: broadening patient access to Ekso Indego Personal and building upon its growing CMS claim pipeline for the device, and further bolstering demand for its legacy EksoNR device.

Management Comments

• We are pleased to close out 2024 with record fourth quarter revenue, improved gross margin and growing interest in our unrivalled portfolio of Enterprise Health and Personal Health devices, said Scott Davis, the Company's Chief Executive Officer.

Industry Context

Ekso Bionics operates in the exoskeleton technology market, serving both medical and industrial sectors. The company's focus on improving health and quality of life through advanced robotics aligns with broader trends in healthcare and workplace safety.

Comparison to Industry Standards

• It is difficult to compare Ekso Bionics directly to industry standards due to the niche nature of the exoskeleton market.
• ReWalk Robotics is a competitor in the medical exoskeleton space, but their financial performance and market focus may differ.
• Larger robotics companies like ABB or KUKA offer industrial automation solutions, but their exoskeleton offerings are typically a smaller part of their overall business.

Stakeholder Impact

• Shareholders may view the improved financial performance and growth strategies positively.
• Employees may benefit from the company's growth and expansion.
• Patients and industrial users could gain access to advanced exoskeleton technology.
• Suppliers may see increased demand for components and materials.

Next Steps

• The company plans to focus on broadening patient access to Ekso Indego Personal and building upon its growing CMS claim pipeline.
• The company aims to further bolster demand for its legacy EksoNR device.

Key Dates